myTomorrows Raises $29M to Expand Global Access to New Therapies

Investment by Avego will prolong attain, speed up AI innovation, and deepen trade partnerships.

myTomorrows, a well being expertise firm that connects sufferers with all attainable pre-approval therapies, right now introduced the shut of a $29 million financing with Avego. Avego’s progress fairness funding will gas the worldwide enlargement of myTomorrows’ built-in pharma options to make rising therapies extra equitable and accessible for sufferers globally.

With greater than 300 million sufferers worldwide dealing with situations with out accepted therapy choices, and over 10,000 therapies presently in improvement or awaiting approval – myTomorrows is addressing certainly one of healthcare’s most pressing challenges: bridging the hole between scientific development and affected person entry to pre-approval therapies, which embody scientific trials and expanded entry applications (EAPs).

The new funding will speed up myTomorrows’ worldwide progress and additional develop its AI-driven world platform that connects physicians and their sufferers, trial websites and BioPharma companions to streamline entry and perception. It can even strengthen collaborations with trade companions to shorten scientific improvement timelines and improve real-world knowledge capabilities, supporting proof era and regulatory perception.

“This funding marks a pivotal step in our journey to give each affected person, irrespective of the place they stay, a good shot at tomorrow’s therapies,” stated Michel van Harten, CEO of myTomorrows. “Avego’s intensive experience in life sciences, notably BioPharma, might be instrumental as we scale our platform and broaden our affect throughout the worldwide well being panorama.”

“Avego is proud to assist myTomorrows in its mission to remodel how sufferers and physicians entry therapies in improvement,” stated James Flexner, Managing Partner at Avego. “We imagine myTomorrows is uniquely positioned to take away limitations for sufferers and suppliers whereas serving as an important associate to BioPharma.”

Ronald Brus, Founder and Board Member of myTomorrows, added: “When we based myTomorrows in 2012, we envisioned a greater means to join sufferers with promising therapies – one that enhances drug improvement and expands entry to innovation. This funding marks the start of a subsequent part of accelerated progress and worldwide affect.”

Today, myTomorrows presents the world’s most complete AI-powered platform for pre-approval therapies, having already helped greater than 16,900 sufferers entry therapies in additional than 133 international locations. Through its highly effective expertise, the corporate helps sufferers and physicians with skilled navigation companies, therapy matching, and streamlined entry to scientific trials and expanded entry applications.

For BioPharma companions, myTomorrows gives scientific trial recruitment, expanded entry options, and real-world knowledge assortment. For trial websites, the platform presents a unified referral administration system that enhances trial visibility and permits real-time standing updates. By connecting all stakeholders throughout the healthcare ecosystem and mixing subsequent era expertise with customized assist, myTomorrows continues to speed up the supply of latest therapies to sufferers in want.

As a default gateway for pre-approval therapies, myTomorrows is constructing the infrastructure for a brand new period of therapy entry – one outlined by AI-enabled transformation, adaptive regulation, and empowered sufferers that take an energetic function of their care. Embedded inside healthcare programs worldwide, its platform gives clear, unbiased, and actionable pathways to rising therapies, guaranteeing breakthroughs attain those that want it most, precisely when it issues.

The publish myTomorrows Raises $29M to Expand Global Access to New Therapies first appeared on AI-Tech Park.